- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05124951
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
The Efficacy of Whole-ventricle Irradiation Plus Primary Boost in Patients With Localized Basal Ganglia Germ Cell Tumors: Prospective Phase II Study
Primary endpoint
- three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation
- Health-related quality of life measured by PedsQL 4.0 and SF-36
Second endpoint
- three-year overall survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation
- Adverse effects of chemoradiotherapy measured by NCI CTCAE 5.0
Study Overview
Status
Conditions
Detailed Description
Intracranial germ cell tumors originating from the basal ganglia area are rare, accounting for less than 20% of patients. Radiotherapy played a vital role in the treatment of this malignancy. However, the optimal target volume is still undetermined.
Our study regarding relapse patterns of different radiation volumes showed that the ventricular system and ipsilateral frontal lobe were at risk of relapse after focal radiotherapy. Although craniospinal irradiation (CSI) and whole-brain irradiation (WBI) could significantly reduce the relapse in the above areas, the adverse effect on the quality of life is still a concern. As a result, the investigators proposed whole-ventricular irradiation (WVI) in patients with localized basal ganglia germ cell tumors. In order to evaluate its efficacy and safety, the investigators designed this phase II study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Bo Li, MD,PhD
- Phone Number: (86)10-59975581
- Email: libo@bjtth.org
Study Locations
-
-
-
Beijing, China, 100070
- Recruiting
- Beijing Tiantan Hospital
-
Contact:
- Bo Li, MD,PhD
- Phone Number: (86)10-59975581
- Email: libo@bjtth.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Stratum I: germinoma
Inclusion Criteria:
- 3 years ≤ age ≤ 30 years
- Newly diagnosed
- Unilateral basal ganglia/thalamus lesion
- Germinoma:Histologically confirmed; and/or serum and/or CSF beta-HCG elevation (≤50IU/L); AFP negative
- No radiological evidence of additional lesions in the CNS
- Negative CSF cytology test
- Adequate organ function
- Written informed consent
Exclusion Criteria:
- Bilateral basal ganglia/ thalamus lesions
- Synchronous pineal or sellar/suprasellar lesion
- Diabetes insipidus
- With extracranial lesion(s)
- Serum/CSF β-HCG >50IU/L without histology
- Mature teratoma with normal tumor markers
- Inadequate organ function
- Poor compliance
Stratum II: non-germinomatous germ cell tumors
Inclusion Criteria:
- 3 years ≤ age ≤ 30 years
- Newly diagnosed
- Unilateral basal ganglia/thalamus lesion
- NGGCTs: Histologically confirmed; and/or serum and/or CSF AFP elevation; beta-HCG≥500IU/L
- No radiological evidence of additional lesions in the CNS
- Negative CSF cytology test
- Adequate organ function
- Written informed consent
Exclusion Criteria:
- Bilateral basal ganglia/ thalamus lesions
- Synchronous pineal or sellar/suprasellar lesion
- Diabetes insipitus
- With extracranial lesion(s)
- 50IU/L<serum/CSF β-HCG <500IU/L without histology
- Mature teratoma with normal AFP and β-HCG <500IU/L
- Inadequate organ function
- Poor compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: iGCTS
Stratum I (Germinoma) Patients who achieved complete response after induction chemotherapy will receive WVI 2400cGy/15f plus primary boost 640cGy/4f. Stratum II (NGGCTs) At the time of response evaluation before radiotherapy, those with complete response or residue disease <1.5cm will receive WVI 3060cGy/17f plus primary boost 2340cGy/13f. |
Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year event-free survival
Time Frame: From the enrollment to the event (relapse or death of any cause), approximately 3 years. The patients will receive long-term follow-up including MRI and serum tumor markers examination every 3 months until 36 months.
|
Event-free survival (DFS) is calculated from the date of enrollment to the date of an event (relapse or death of any cause).
|
From the enrollment to the event (relapse or death of any cause), approximately 3 years. The patients will receive long-term follow-up including MRI and serum tumor markers examination every 3 months until 36 months.
|
Change of score of the QoL questionnaire (PedsQL 4.0 : Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales, Chinese edition)
Time Frame: Score will be obtained at baseline, 6 months posttreatment, yearly through 3 years posttreatment
|
The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions.
The Scale comprises parallel patient self-report and parent proxy-report formats.
The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.
(age ≤18 years)
|
Score will be obtained at baseline, 6 months posttreatment, yearly through 3 years posttreatment
|
Change of score of the QoL questionnaire (Short form-36)
Time Frame: Evaluation will be conducted at baseline, 6 months posttreatment, yearly through 3 years posttreatment
|
Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH).
Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year.
The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL.
Physical component score (PCS) and mental component score (MCS) were also calculated.
(Age >15 years)
|
Evaluation will be conducted at baseline, 6 months posttreatment, yearly through 3 years posttreatment
|
Change of score of Chinese Wechsler Intelligence Scale for Children
Time Frame: Score will be obtained at baseline, 6 months posttreatment, yearly through 3 years posttreatment
|
The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University.
The C-WISC consists of 11 individual tests that include six verbal tests [Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)] and five performance tests [Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)].
Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained.
Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively .
|
Score will be obtained at baseline, 6 months posttreatment, yearly through 3 years posttreatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-year overall survival
Time Frame: From the enrollment to the death of any cause or last follow-up, approximately 3 years.The patients will receive long-term follow-up including MRI and serum tumor markers examination every 3 months until 36 months.
|
Overall survival is determined from the date of diagnosis to the date of death of any cause or the last follow-up visit
|
From the enrollment to the death of any cause or last follow-up, approximately 3 years.The patients will receive long-term follow-up including MRI and serum tumor markers examination every 3 months until 36 months.
|
Short-term adverse effects of treatments
Time Frame: From the beginning to the completion of chemoradiotherapy, approximately 6 months. Grade 3/4 toxicities will be documented
|
NCI CTCAE 5.0 will be used for adverse effects evaluation
|
From the beginning to the completion of chemoradiotherapy, approximately 6 months. Grade 3/4 toxicities will be documented
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tao Jiang, MD, PhD, Beijing Tiantan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Cysts
- Connective Tissue Diseases
- Nervous System Neoplasms
- Mucinoses
- Neoplasms, Germ Cell and Embryonal
- Central Nervous System Neoplasms
- Ganglion Cysts
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Carboplatin
- Etoposide
- Etoposide phosphate
- Cisplatin
- Ifosfamide
Other Study ID Numbers
- CHN-IGCT-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Germ Cell CNS Tumor, Childhood
-
Chengcheng GuoRecruitingSurgery | Intracranial Germ Cell Tumor | Intracranial Germ Cell CNS Tumor, ChildhoodChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedExtragonadal Germ Cell Tumor | Childhood Germ Cell TumorCanada, United States, Australia, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Teratoma | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor | Childhood Embryonal Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Extragonadal Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
The Hospital for Sick ChildrenActive, not recruitingChildhood Solid Tumor | Recurrent Childhood CNS Tumor | Ependymoma, Recurrent ChildhoodUnited States, Canada, Australia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Ovarian Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor
-
City of Hope Medical CenterActive, not recruitingUnspecified Childhood Solid Tumor, Protocol Specific | Solid Tumor | Ewing Sarcoma | Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Adult Brain Tumor | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Brain Stem Glioma | Childhood Central Nervous System Germ Cell Tumor | Childhood Central Nervous System Choriocarcinoma | Childhood Central Nervous System Germinoma | Childhood Central Nervous System Mixed Germ Cell... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Yolk Sac Tumor | Recurrent Ovarian Germ Cell Tumor | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent Malignant Testicular Germ Cell Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Central Nervous System Metastases | Childhood Central Nervous System Germ Cell Tumor | Childhood Central Nervous System Choriocarcinoma | Childhood Central Nervous System Germinoma | Childhood Central Nervous System Mixed Germ Cell Tumor | Childhood Central Nervous System Teratoma and other conditionsUnited States, Canada
-
UNICANCERTerminatedTesticular Germ Cell Tumor | Ovarian Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell TumorFrance
Clinical Trials on Whole-ventricle irradiation
-
Yonsei UniversityRecruiting
-
Danish Breast Cancer Cooperative GroupDanish Cancer Society; Danish Center for Interventional Research in Radiation...Active, not recruitingBreast CarcinomaDenmark
-
Medical University InnsbruckMarcel Seiz-Rosenhagen MD, PD; Meinhard Nevinny-Stickel MD, Prof.; Christian... and other collaboratorsUnknownMetastatic Malignant Neoplasm to the Adult BrainAustria
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruiting
-
Regione Emilia-RomagnaCompleted
-
Azienda Ospedaliero-Universitaria CareggiCompletedBreast Cancer | Radiotherapy Side EffectItaly
-
Sun Yat-sen UniversityGuilin Medical College; First People's Hoapital of FoshanCompletedNasopharyngeal CarcinomaChina
-
Samsung Medical CenterMinistry of Health, Republic of Korea; Korean Radiation Oncology GroupActive, not recruitingBreast NeoplasmKorea, Republic of
-
National Cancer Institute, EgyptCompleted
-
Ontario Clinical Oncology Group (OCOG)RecruitingBreast Neoplasm Female | Radiotherapy | Cosmetic OutcomeCanada